ReGen Biologics Inc. (RGBOQ) Financials Nov 12, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for ReGen Biologics Inc.
Fiscal year is January-December. All values USD millions. 2004 2005 2006 2007 2008 5-year trend
Sales/Revenue 504,000 570,000 586,000 986,000 1.37M
Cost of Goods Sold (COGS) incl. D&A 371,000 568,000 506,000 465,000 693,000
COGS excluding D&A 318,000 528,000 441,000 375,000 591,000
Depreciation & Amortization Expense 53,000 40,000 65,000 90,000 102,000
Depreciation - - - - -
Amortization of Intangibles - - - - -
Gross Income 133,000 2,000 80,000 521,000 681,000
2004 2005 2006 2007 2008 5-year trend
SG&A Expense 6.92M 11.47M 12.63M 10.82M 9.82M
Research & Development 3.66M 7.5M 6.76M 3.97M 4.03M
Other SG&A 3.26M 3.97M 5.87M 6.86M 5.8M
Other Operating Expense 0 58,000 0 0 0
Unusual Expense 0 0 0 0 0
EBIT after Unusual Expense 0 0 0 0 0
Non Operating Income/Expense 3,000 4,000 (4,000) 0 0
Non-Operating Interest Income 138,000 389,000 312,000 366,000 59,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 137,000 256,000 413,000 442,000 869,000
Gross Interest Expense 137,000 256,000 413,000 442,000 869,000
Interest Capitalized 0 0 0 0 0
Pretax Income (6.78M) (11.39M) (12.66M) (10.38M) (9.95M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (6.78M) (11.39M) (12.66M) (10.38M) (9.95M)
Minority Interest Expense 0 0 0 0 0
Net Income (6.78M) (11.39M) (12.66M) (10.38M) (9.95M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (6.78M) (11.39M) (12.66M) (10.38M) (9.95M)
Preferred Dividends 762,000 219,000 110,000 360,000 2.76M
Net Income Available to Common (7.54M) (11.61M) (12.77M) (10.74M) (12.71M)
EPS (Basic) (3.60) (3.80) (3.60) (2.00) (2.41)
Basic Shares Outstanding 2.12M 3.02M 3.56M 5.18M 5.28M
EPS (Diluted) (3.56) (3.84) (3.58) (2.07) (1.89)
Diluted Shares Outstanding 2.12M 3.02M 3.56M 5.18M 5.28M
EBITDA (6.73M) (11.49M) (12.49M) (10.21M) (9.04M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for ReGen Biologics Inc.
Fiscal year is January-December. All values USD millions. 2004 2005 2006 2007 2008 5-year trend
Sales/Revenue 504,000 570,000 586,000 986,000 1.37M
Cost of Goods Sold (COGS) incl. D&A 371,000 568,000 506,000 465,000 693,000
COGS excluding D&A 318,000 528,000 441,000 375,000 591,000
Depreciation & Amortization Expense 53,000 40,000 65,000 90,000 102,000
Depreciation - - - - -
Amortization of Intangibles - - - - -
Gross Income 133,000 2,000 80,000 521,000 681,000
2004 2005 2006 2007 2008 5-year trend
SG&A Expense 6.92M 11.47M 12.63M 10.82M 9.82M
Research & Development 3.66M 7.5M 6.76M 3.97M 4.03M
Other SG&A 3.26M 3.97M 5.87M 6.86M 5.8M
Other Operating Expense 0 58,000 0 0 0
Unusual Expense 0 0 0 0 0
EBIT after Unusual Expense 0 0 0 0 0
Non Operating Income/Expense 3,000 4,000 (4,000) 0 0
Non-Operating Interest Income 138,000 389,000 312,000 366,000 59,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 137,000 256,000 413,000 442,000 869,000
Gross Interest Expense 137,000 256,000 413,000 442,000 869,000
Interest Capitalized 0 0 0 0 0
Pretax Income (6.78M) (11.39M) (12.66M) (10.38M) (9.95M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (6.78M) (11.39M) (12.66M) (10.38M) (9.95M)
Minority Interest Expense 0 0 0 0 0
Net Income (6.78M) (11.39M) (12.66M) (10.38M) (9.95M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (6.78M) (11.39M) (12.66M) (10.38M) (9.95M)
Preferred Dividends 762,000 219,000 110,000 360,000 2.76M
Net Income Available to Common (7.54M) (11.61M) (12.77M) (10.74M) (12.71M)
EPS (Basic) (3.60) (3.80) (3.60) (2.00) (2.41)
Basic Shares Outstanding 2.12M 3.02M 3.56M 5.18M 5.28M
EPS (Diluted) (3.56) (3.84) (3.58) (2.07) (1.89)
Diluted Shares Outstanding 2.12M 3.02M 3.56M 5.18M 5.28M
EBITDA (6.73M) (11.49M) (12.49M) (10.21M) (9.04M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
